Navigation Links
Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
Date:2/9/2009

BALTIMORE, Feb. 9 /PRNewswire/ -- Celsis In Vitro Technologies (Celsis IVT), a division of Celsis International plc, a Chicago-based life science products and laboratory services company, and Wisconsin-based Promega Corp will take the trial and guesswork out of ADME-Tox testing in primary hepatocytes. Celsis IVT is pre-qualifying lots of its extensive cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including the P450-Glo(TM) CYP Assay used to study cytochrome P450 gene induction and inhibition and the GSH-Glo(TM) Glutathione Assay for investigating mechanisms of hepatotoxicity.

"Researchers are looking for validated solutions that are predictive," said Dr. James Cali, lead scientist for ADME-Tox at Promega. "Providing pre-qualified cryoplateable hepatocytes that work the first time and every time with our luminescent reagents has always been a goal for Promega. By validating lots from their extensive inventory in advance, Celsis IVT will help our customers save additional time in their research," he explained. "Together, we are taking the guesswork out of hepatocyte analysis."

Determining whether a particular lot of hepatocytes will work for a given application is time-consuming and costly. Much of the effort involves trial and error. Even when a suitable lot of hepatocytes is identified, current LC/MS technologies for measuring gene expression, enzyme activity or metabolite formation are expensive or require lengthy incubations times that often involve working evening or weekend hours. This collaborative effort between Promega and Celsis IVT will enable customers to quickly and easily identify and select both products that have been validated to work together, saving customers valuable time and resources, increasing efficiency and leading to the faster development of safe drugs.

"Celsis IVT is pleased to be working closely with Promega to help deliver a complete, validated and predictive solution to customers in the area of ADME-Tox assays," said Philip Vorwald, vice president and general manager of Celsis IVT. "Promega's P450-Glo CYP and GSH-Glo ADME-Tox assays enable scientists to get results faster. Now with our pre-qualified cell lots, Promega customers can eliminate the guesswork involved in testing cell lots, save analysis time and money, and have the greatest confidence in their results."

The two companies are collaborating on scientific presentations and publications demonstrating effective applications of the validated tools for ADME-Tox studies.

About Celsis

Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas: rapid microbial detection systems, analytical laboratory services and ADME-Tox in vitro products and services. The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers in addition to ensuring product quality and safety for consumers. Celsis In Vitro Technologies helps companies reduce the time and cost of drug development by supplying in vitro testing products to the pharmaceutical and biotechnology industries for screening drug compounds early in the discovery process. More information is online at http://www.celsis.com.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in ADME-Tox, cellular analysis, genomics, proteomics and molecular diagnostics. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in twelve countries and 54 global distributors. Annual sales exceed $220 million. For more information about Promega, visit http://www.promega.com.


'/>"/>
SOURCE Celsis In Vitro Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
2. Celsis Receives Frost & Sullivan 2008 Best Practices Award
3. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
4. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
5. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
6. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
7. JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market
8. New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers
9. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
10. EAU Technologies Receives Patent for Empowered Water(TM)
11. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Researchers from a new study are stating that if levels of the blood ... this indicates there is still remaining prostate cancer cells that are more likely to come ... always been an indicator of whether a man’s prostate cancer is growing or not,” ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it will hold ... testing lab equipment from two different leading institutes. This highly specialized laboratory equipment is ... United States. This 1-day online auction will take place on BidMed’s website ...
(Date:1/18/2017)... ... 2017 , ... Thirty-six startup companies in University City and Center City have ... and Economic Development in 2016 as part of the Keystone Innovation Zone (KIZ) Tax ... Zone and represent the highest number of awards to the largest number of companies ...
(Date:1/18/2017)... 2017  HUYA Bioscience International, (HUYA), the leader in ... pharmaceutical innovations, announced today a strategic collaboration agreement ... Company (referred to as CAS Innovation). The collaboration will ... leading scientists at CAS to meet the medical needs ... the first company to have recognized China,s ...
Breaking Biology Technology:
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/8/2016)... 8, 2016 Market Research Future published a half cooked ... Mobile Biometric Security and Service Market is expected to grow over ... Market Highlights: ... Mobile Biometric Security and Service ... increasing need of authentication and security from unwanted cyber threats. The ...
Breaking Biology News(10 mins):